Source: International Congress 2019 – Asthma treatment: cohorts and real-world studies
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Janson (Uppsala, Sweden), B. Nwaru (Lund, Sweden), L. Hasvold (Sodertalje, Sweden), F. Wicklund (Uppsala, Sweden), G. Telg (Sodetalje, Sweden), M. Ekstrom (Gothenburg, Sweden). Use of short-acting beta-2 agonists (SABA) and exacerbations in a nationwide Swedish asthma cohort (HERA). 2554

Member's Comments

No comment yet.

Related content which might interest you: Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination can decrease mortality of COPD patients, a nationwide population-based cohort study in Taiwan Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012 Should guidelines be revised for add-on therapy in asthma? A 2 year randomized pragmatic equivalence trial of leukotriene antagonists (LTRAs) and long-acting beta agonists (LABAs) with inhaled corticosteroids (ICS) in primary care Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care Year: 2008 Trends of short-acting beta-agonist (SABA) surrounding days of high use in asthma and COPD Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases Year: 2019 Safety of long-acting β-agonist (LABA) withdrawal in patients in two clinical asthma trials Source: Annual Congress 2012 - Different ways to phenotype asthma Year: 2012 A new user cohort study comparing the risk of pneumonia in inhaled corticosteroid (ICS) vs. long-acting bronchodilator (LABD) regimens in COPD Source: Annual Congress 2013 –Risk factors for COPD and lung function decline Year: 2013 Role of tiotropium in reducing exacerbations in COPD patients when added to long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS): The OUTPUL study Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 Low dose inhaled corticosteroids (ICS) and short-acting beta-agonists (SABA) or long-acting beta-agonists (LABA) need in children and adolescents with asthma steps 1 and 2: what is the evidence? Source: Virtual Congress 2020 – Which paediatric asthma guidelines are the most appropriate for children and adolescents? Year: 2020 Efficacy and safety of abediterol, a long-acting beta2-adrenergic agonist (LABA); three phase II trials in asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Efficacy and safety of inhaled corticosteroid‘s (ICS) and long-acting beta-agonist‘s (LABA) combination in asthma (A) patients Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004 Predictors of excessive short-acting beta2-agonist use and asthma exacerbations: a retrospective analysis of a Polish prescription database. Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 Nighttime short-acting beta-agonist (SABA) in asthma and COPD Source: International Congress 2019 – Impact of sleep-disordered breathing in other diseases Year: 2019 Real-life use and impact of inhaled steroids (ICS) and leukotriene receptor antagonists (LTRA) monotherapy in children with asthma Source: Annual Congress 2010 - Paediatric asthma treatment and monitoring Year: 2010 LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015 What predicts short-acting beta agonist (SABA) monotherapy use in children? Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004 Overuse of short-acting beta-agonists (SABA) and risk factors among patients with asthma Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma Source: International Congress 2017 – Techniques to treat asthma Year: 2017 Long-acting anti-muscarinic agents (LAMA) frequency of use and clinical features of patients with severe asthma in real-life setting: data from the Severe Asthma Network in Italy (SANI) registry Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts Year: 2019 Should asthma guidelines be rewritten for initial controller therapy: a 2 year randomized pragmatic equivalence trial of leukotriene antagonists (LTRAs) and inhaled corticosteroids (ICS) in primary care Source: Annual Congress 2008 - Rationale of self-education in asthma therapy Year: 2008 Combination of inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA) versus similar ICS dose in children and adults with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005 First choice in persistent asthma: inhaled corticosteroids (ICS) or ICS + long-acting beta2-agonist (LABA) combination in steroid-naïve patients? Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids Year: 2004